Fig 1.
Acute injection of METH reduces ICSS thresholds.
ICSS thresholds (A) and response latencies (B) (expressed as percent of baseline, mean ± SEM) following s.c. injection of METH (0–0.56 mg/kg) in Experiment 1a. ** Significantly different from 0 mg/kg METH, p < 0.01.
Fig 2.
Spontaneous withdrawal from a chronic METH infusion elevates ICSS thresholds: reversal by acute METH.
ICSS thresholds (A) and response latencies (B) (expressed as percent of baseline, mean ± SEM) during (“pump in” phase) and after (“pump out” phase) chronic exposure to saline or METH (10 mg/kg/day) in Experiment 1b. Rats were administered s.c. SAL or METH 0.3 mg/kg prior to the first session of the pump out phase. *, ** Significantly different from SAL+ SAL at that session, p < 0.05 or 0.01. # METH + METH significantly different from METH + SAL at that session, p < 0.01. For clarity, significant differences in marginal means between the METH + SAL and METH + METH groups compared to the SAL + SAL group during the pump in phase are not shown in Fig. 2A (see text for further details).
Table 1.
Mean (±SEM) ICSS thresholds (in μA) and response latencies (in sec) in experimental groups during baseline sessions in Experiments 1b, 2, and 3.
Fig 3.
MAb7F9 attenuates the ability of acute METH to reduce baseline ICSS thresholds, ICSS thresholds (A) and response latencies (B) (expressed as percent of baseline, mean ± SEM) following i.v. infusion of vehicle (PBS) or mAb (30, 100, or 200 mg/kg) followed by repeated daily injections of s.c. SAL or 0.3 mg/kg METH in Experiment 2.
** Significantly different from PBS + SAL at that session, p < 0.01. #, ## 200 mAb + METH significantly different from PBS + METH at that session, p < 0.05 or 0.01. For clarity, significant differences in marginal means between groups are not shown in Fig. 3A or 3B.
Fig 4.
MAb7F9 modestly attenuates the ability of acute METH to reverse elevations in ICSS thresholds during METH withdrawal.
ICSS thresholds (A) and response latencies (B) (expressed as percent of baseline, mean ± SEM) in rats administered i.v. PBS or 200 mg/kg mAb immediately following cessation of a chronic METH infusion, followed 20 hr later by s.c. SAL or 0.3 mg/kg METH in Experiment 3. *, ** Significantly different from SAL-injected animals for that mAb dose, p < 0.05 or 0.01. #,mAb 200 + METH significantly different from PBS + METH, p < 0.05.